Your browser doesn't support javascript.
loading
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Hansson, Markus; Gimsing, Peter; Badros, Ashraf; Niskanen, Titti Martinsson; Nahi, Hareth; Offner, Fritz; Salomo, Morten; Sonesson, Elisabeth; Mau-Sorensen, Morten; Stenberg, Yvonne; Sundberg, Annika; Teige, Ingrid; Van Droogenbroeck, Jan; Wichert, Stina; Zangari, Maurizio; Frendeus, Björn; Korsgren, Magnus; Poelman, Martine; Tricot, Guido.
Affiliation
  • Hansson M; Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden. markus.hansson@med.lu.se.
  • Gimsing P; Department of Hematology, Copenhagen University and Rigshospitalet, Copenhagen, Denmark.
  • Badros A; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
  • Niskanen TM; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Nahi H; Department of Medicine, Karolinska University Hospital, Huddinge, Sweden.
  • Offner F; Department of Hematology, Ghent University Hospital, Ghent, Belgium.
  • Salomo M; Department of Hematology, Copenhagen University and Rigshospitalet, Copenhagen, Denmark.
  • Sonesson E; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Mau-Sorensen M; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Stenberg Y; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Sundberg A; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Teige I; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Van Droogenbroeck J; Department of Hematology, AZ St Jan Hospital, Bruges, Belgium.
  • Wichert S; Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden.
  • Zangari M; Myeloma Institute, University of Arkansas, Little Rock, Arkansas.
  • Frendeus B; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Korsgren M; Clinical Development, BioInvent International AB, Lund, Sweden.
  • Poelman M; Medical and Scientific Department, Covance Inc., Brussels, Belgium.
  • Tricot G; Department of Internal Medicine, University of Iowa, Iowa City, Iowa.
Clin Cancer Res ; 21(12): 2730-6, 2015 Jun 15.
Article in En | MEDLINE | ID: mdl-25712687
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Sweden
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Sweden